NASDAQ: ICUSeastar Medical Holding Corp Stock
$1.29+0.03 (+2.38%)
Updated Apr 30, 2025
ICU Price
$1.29
Fair Value Price
$0.52
Market Cap
$11.25M
52 Week Low
$1.11
52 Week High
$13.85
P/E
-0.19x
P/B
-5.15x
P/S
53.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$135.00k
Earnings
-$24.83M
Gross Margin
100%
Operating Margin
-18,209.63%
Profit Margin
-18,392.6%
Debt to Equity
-3.13
Operating Cash Flow
-$16M
Beta
0.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ICU Overview
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ICU's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ICU
Ranked#215 of 462
Ranked#215 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important ICU news, forecast changes, insider trades & much more!
ICU News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ICU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ICU ($1.29) is overvalued by 150.33% relative to our estimate of its Fair Value price of $0.52 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ICU ($1.29) is not significantly undervalued (150.33%) relative to our estimate of its Fair Value price of $0.52 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ICU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ICU due diligence checks available for Premium users.
Valuation
ICU fair value
Fair Value of ICU stock based on Discounted Cash Flow (DCF)
Price
$1.29
Fair Value
$0.52
Overvalued by
150.33%
ICU ($1.29) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ICU ($1.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ICU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ICU price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
-162.28x
Market
29.18x
ICU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5.15x
Industry
4.45x
ICU's financial health
Profit margin
Revenue
$67.0k
Net Income
-$4.4M
Profit Margin
-6,595.5%
ICU's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ICU's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.7M
Liabilities
$6.8M
Debt to equity
-3.13
ICU's short-term liabilities ($6.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ICU's short-term assets ($3.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ICU's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ICU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.7M
Investing
$0.0
Financing
$4.4M
ICU's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ICU vs Biotech Stocks
Seastar Medical Holding Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.